Packing biological material for hemostasis and preparation method thereof
By pretreatment, cross-linking and post-treatment of the submucosal layer of the small intestine, filling biological materials with good water resistance were prepared, which solved the problems of poor water resistance and easy swelling of traditional hemostatic materials, and achieved appropriate degradation speed and hemostatic effect. In various hemostasis conditions, the patient's pain is reduced.
Patent Information
- Application Number
- CN202411246340.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-12-03
AI Technical Summary
Traditional hemostatic materials have poor water resistance, are prone to swelling, and have too fast degradation, making it difficult to effectively solve the hemostatic problem of large deep cavity and wounds, especially the secondary bleeding caused by postoperative traction.
By pretreatment, crosslinking and post-treatment of the submucosal layer of the small intestine, a filling biological material with good water resistance was prepared. The crosslinking treatment solution used was made of catechol, potassium persulfate, sodium periodate and shell poly Sugar quaternary ammonium salts are composed and reacted at different pH values, and finally the blocked biomaterial is obtained by lyophilization.
The material has improved water resistance, suitable degradation speed, and is not easy to stick or curl, reducing the pain of patients. It is suitable for various hemostasis conditions and has good market application prospects.
Smart Images

Figure BDA0005030873110000031 
Figure BDA0005030873110000041
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomaterials, and particularly relates to a biomaterial for hemostasis and a preparation method thereof. Background Art
[0002] Traditional clinical hemostasis methods include suturing and compression, but when faced with surgeries involving deep cavities and large wounds, traditional hemostasis methods are difficult to be effective. In addition, traditional hemostasis methods cannot solve problems such as secondary bleeding caused by postoperative traction. Therefore, hemostatic materials came into being. Among them, the hemostatic effect of pure collagen biomaterials is very obvious. Collagen can cause platelets to aggregate, thereby stimulating platelets to release coagulation factors and achieve a hemostatic effect. However, this type of material has poor water resistance, easily swells in water, and degrades too quickly. Therefore, it is necessary to develop a new hemostatic material. Summary of the invention
[0003] The first aspect of the present invention provides a biomaterial for hemostasis, which is obtained by pre-treating, cross-linking and post-treating the submucosa of the small intestine.
[0004] The present invention also provides a method for preparing a biomaterial for hemostasis, comprising the following steps:
[0005] (1) Pretreatment: Mechanically peeling the small intestinal tissue of the pig to obtain the small intestinal submucosa; then defatting and removing antigens to obtain the pretreated protein material;
[0006] (2) Cross-linking: cross-linking the protein material obtained in step (1) in a cross-linking treatment solution to obtain a modified protein material; wherein the cross-linking treatment solution is composed of catechol solution, potassium persulfate solution, sodium periodate solution and chitosan quaternary ammonium salt; (3) Post-treatment: adding an alkaline solution to the modified protein material obtained in step (2) to adjust the pH value to alkaline, reacting for 24-36 hours; then adjusting the pH to acidic or neutral, filtering, taking the solid film layer, washing with water and then freeze-drying to obtain a plugging biomaterial.
[0007] Preferably, the defatting in step (1) is specifically as follows: small intestinal submucosal layer, isopropanol and anhydrous ethanol are mixed in a ratio of 1 g: 5-10 mL: 0.1-1 mL, extracted and filtered, solids are taken and washed.
[0008] Preferably, the antigen removal in step (1) is specifically as follows: the defatted small intestinal submucosal layer is extracted and filtered in an alkaline aqueous solution of 3-4 wt% sodium chloride, and the solid is taken out and washed.
[0009] In step (1), when the defatted small intestinal submucosa is extracted in an alkaline aqueous solution of 3-4wt% sodium chloride, the ratio of the defatted small intestinal submucosa to the alkaline aqueous solution of 3-4wt% sodium chloride is (0.001-1g):(1-100mL).
[0010] Preferably, the volume ratio of the catechol solution, potassium persulfate solution and sodium periodate solution in step (2) is 1-2:0.1-0.5:0.1-0.2.
[0011] Preferably, in the cross-linking treatment solution, the concentration of chitosan quaternary ammonium salt is 5-10 wt %.
[0012] Preferably, the concentration of the catechol solution is 4-8 mg / mL; the concentration of the potassium persulfate solution is 10-15 mg / mL; and the concentration of the sodium periodate solution is 0.1-1 mg / mL.
[0013] Preferably, the crosslinking modification time in step (2) is 1 h to 1.5 h.
[0014] Preferably, the post-treatment of step (3) is as follows: adding an alkaline solution to the modified protein material obtained in step (2) to adjust the pH value to 8.2-9.5, and reacting for 24-36 hours; then adjusting the pH to 6-7.5, filtering, taking the solid film layer, washing with water and then freeze-drying to obtain the plugging biomaterial.
[0015] Beneficial Effects
[0016] The invention has good water resistance, low swelling rate and suitable degradation speed; it is degradable, not easy to adhere, not easy to curl, and can pull the wound, thus reducing the pain of the patient, and is suitable for hemostasis in various situations, and has good market application prospects. DETAILED DESCRIPTION
[0017] Below in conjunction with specific embodiment, further elaborate the present invention.Should be understood that these embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention.In addition, should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall equally within the scope limited by the appended claims of the application.Example materials used are all commercially available, and in the present invention, chitosan quaternary ammonium salt is purchased from Kanglang Biology, model KL10818.
[0018] Example 1
[0019] (1) Pretreatment: Mechanically peeling the small intestinal tissue of the pig to obtain the small intestinal submucosa; then defatting and removing antigens to obtain the pretreated protein material;
[0020] Degreasing: small intestinal submucosal layer, isopropanol, and anhydrous ethanol were mixed in a ratio of 1g:6mL:0.7mL, extracted for 10 hours, filtered, and the solid was taken and washed with deionized water for 20-40 minutes.
[0021] Antigen removal: Add 3 wt% sodium chloride in a sodium hydroxide solution to the defatted solid at a ratio of 0.02:20 mL, extract for 10 hours, filter, take the solid, and wash with deionized water for 20-40 minutes.
[0022] (2) Cross-linking: The protein material obtained in step (1) is cross-linked and modified in a cross-linking treatment solution for 1 hour to obtain a modified protein material; wherein the cross-linking treatment solution is composed of catechol solution, potassium persulfate solution, sodium periodate solution and chitosan quaternary ammonium salt; in the cross-linking treatment solution, the concentration of chitosan quaternary ammonium salt is 5wt%; the volume ratio of catechol solution, potassium persulfate solution and sodium periodate solution is 1:0.5:0.2. The cross-linking treatment solution is obtained by mixing catechol solution, potassium persulfate solution and sodium periodate solution, and then adding chitosan quaternary ammonium salt.
[0023] (3) Post-treatment: Add sodium hydroxide aqueous solution to the modified protein material obtained in step (2) to adjust the pH value to 9, immerse the modified protein material in the sodium hydroxide aqueous solution, and react for 24 hours; then add acetic acid aqueous solution to adjust the pH to 7.4, filter, take the solid film layer, wash with water and then freeze-dry to obtain the plugging biomaterial.
[0024] Example 2
[0025] The difference from Example 1 is that in step (2), during cross-linking, the volume ratio of the catechol solution, the potassium persulfate solution, and the sodium periodate solution is 1:0.4:0.1.
[0026] Comparative Example 1
[0027] The difference from Example 1 is that in step (2), during cross-linking, the cross-linking treatment solution only consists of catechol solution, potassium persulfate solution and sodium periodate solution, and no chitosan quaternary ammonium salt is added.
[0028] Comparative Example 2
[0029] The difference from Example 1 is that in step (2), during cross-linking, the cross-linking treatment solution only consists of potassium persulfate solution, sodium periodate solution and chitosan quaternary ammonium salt, and no catechol solution is added.
[0030] Comparative Example 3
[0031] The difference from Example 1 is that in step (2), during cross-linking, the volume ratio of the catechol solution, the potassium persulfate solution, and the sodium periodate solution is 1:0.9:0.6.
[0032] Comparative Example 4
[0033] The difference from Example 1 is that step (3) is post-processing: the modified protein material obtained in step (2) is added to PBS buffer to adjust the pH value to 7.4, the modified protein material is immersed in the PBS buffer, reacted for 24 hours, filtered, the solid film layer is taken, washed with water and then freeze-dried to obtain the plugging biomaterial.
[0034] Performance Testing
[0035] ① Porosity: The cross-sectional morphology of the materials obtained in Examples 1-2 and Comparative Examples 1-4 was characterized by scanning electron microscopy, and the porosity was calculated therefrom. The results are shown in Table 1:
[0036] Table 1
[0037] Example Porosity (%) Example 1 91.2 Example 2 90.6 Comparative Example 1 65.3 Comparative Example 2 74.3 Comparative Example 3 71.4 Comparative Example 4 80.7
[0038] The greater the porosity, the better the adsorption performance of the material after implantation, which is more conducive to wound hemostasis and trauma recovery.
[0039] ② Swelling rate: The materials obtained in Examples 1-2 and Comparative Examples 1-4 were cut into 1×1 cm fragments, and the mass (m) at this time was weighed. The fragments were immersed in PBS buffer, taken out after 2 hours, and the surface liquid was absorbed with filter paper and weighed again, recorded as m1. Swelling rate = (m1-m) / m×100%. The results are shown in Table 2:
[0040] Table 2
[0041]
[0042]
[0043] The lower the swelling rate, the less pressure it exerts on the tissue, which is more conducive to wound recovery and less likely to cause the wound to bleed again.
[0044] ③ Water resistance effect: Before and after the above swelling test, the compressive stress was measured at room temperature using an Elf3330 dynamic / static multifunctional biomechanical testing machine, and the compression speed was set to 10 mm / min. The results are shown in Table 3:
[0045] Table 3
[0046] Example Compressive stress before swelling (MPa) Compressive stress after swelling (MPa) Example 1 0.42 0.35 Example 2 0.44 0.41 Comparative Example 1 0.36 0.11 Comparative Example 2 0.35 0.15 Comparative Example 3 0.26 0.17 Comparative Example 4 0.39 0.13
[0047] ④ Pyrogenic test: adult healthy rabbits, regardless of gender, were selected, and the packing biomaterials obtained in Example 2 and Comparative Example 3 were respectively injected into the rabbit's ear vein using physiological saline extracts, and the rabbit's rectal temperature was detected. The body temperature difference before and 2 hours after the injection was compared. The temperature difference in Example 2 was 0.16°C, and the temperature difference in Comparative Example 3 was 1.05°C, both of which were lower than 1.4°C.
Claims
1. A biomaterial for hemostasis, characterized in that: It is obtained by pre-treatment, cross-linking and post-treatment of the small intestinal submucosa.
2. A method for preparing the hemostatic packing biomaterial according to claim 1, comprising the following steps: (1) Pretreatment: Mechanically peeling the small intestinal tissue of the pig to obtain the small intestinal submucosa; then defatting and removing antigens to obtain the pretreated protein material; (2) Cross-linking: cross-linking the protein material obtained in step (1) in a cross-linking treatment solution to obtain a modified protein material; wherein: The cross-linking treatment solution is composed of catechol solution, potassium persulfate solution, sodium periodate solution and chitosan quaternary ammonium salt; (3) Post-treatment: Add an alkaline solution to the modified protein material obtained in step (2) to adjust the pH value to alkaline, and react for 24-36 hours; then adjust the pH to weak acid or neutral, filter, take the solid film layer, wash with water, and then freeze-dry to obtain the plugging biomaterial.
3. The preparation method according to claim 2, characterized in that: The defatting in step (1) is specifically as follows: small intestinal submucosal layer, isopropanol and anhydrous ethanol are mixed in a ratio of 1 g: 5-10 mL: 0.1-1 mL, extracted and filtered, solids are collected and washed.
4. The preparation method according to claim 2, characterized in that: The antigen removal in step (1) is specifically as follows: the defatted small intestinal submucosal layer is extracted and filtered in an alkaline aqueous solution of 3-4 wt% sodium chloride, and the solid is taken out and washed.
5. The preparation method according to claim 2, characterized in that: In the cross-linking treatment solution of step (2), the volume ratio of catechol solution, potassium persulfate solution and sodium periodate solution is 1-2:0.1-0.5:0.1-0.
2.
6. The preparation method according to claim 2 or 5, characterized in that: In the cross-linking treatment solution, the concentration of chitosan quaternary ammonium salt is 5-10wt%.
7. The preparation method according to claim 2 or 5, characterized in that: The concentration of the catechol solution is 4-8 mg / mL; the concentration of the potassium persulfate solution is 10-15 mg / mL; and the concentration of the sodium periodate solution is 0.1-1 mg / mL.
8. The preparation method according to claim 2, characterized in that: The cross-linking modification time in step (2) is 1 h to 1.5 h.
9. The preparation method according to claim 2, characterized in that: The post-treatment of step (3) is as follows: adding an alkaline solution to the modified protein material obtained in step (2) to adjust the pH value to 8.2-9.5, and reacting for 24-36 hours; then adjusting the pH to 6-7.5, filtering, taking the solid film layer, washing with water, and then freeze-drying to obtain the plugging biomaterial.
